Vical signs LOI with AnGes for pandemic influenza program

Oct 08, 2008 (Datamonitor via COMTEX) -- VICL | Quote | Chart | News | PowerRating -- Vical, a developer of biopharmaceutical products, and AnGes MG, a biopharmaceutical company, have signed a non-binding letter of intent indicating their mutual interest to license the development and marketing rights for Vical's pandemic influenza DNA vaccines in Japan to AnGes.

AnGes plans to conduct due diligence on the pandemic influenza DNA vaccines, and both parties intend to negotiate terms and conditions potentially leading to a license, subject to completion of a mutually satisfactory definitive agreement.

AnGes's experience in working with Vical's DNA delivery technology within the Japanese regulatory environment positions the company well to pursue further development in Japan based on Vical's recently announced preliminary Phase I H5N1 pandemic influenza data.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index